Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

Feature Story

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

New HIV therapies have led to a decline in hospital costs for most patients

A nationwide study supported in part by the Agency for Healthcare Research and Quality (HS08578) has found that expenditures for hospital inpatient care for HIV fell more than 40 percent by mid-1997 in the wake of the introduction early the preceding year of highly active combination antiretroviral therapy, a mixture of protease inhibitors and other drugs. The decrease in demand for hospital care, along with a more modest reduction in the use of outpatient care, helped drive down overall treatment expenditures for HIV patients by one-sixth between early 1996 and late 1998.

According to the HIV Cost and Services Utilization Study (HCSUS), which was conducted by a consortium led by RAND Health, the mean monthly expenditures per HIV patient—including expenses for hospital and outpatient care and drug therapy—declined from $1,792 in 1996 to $1,359 roughly a year later and then rose slightly to $1,410 by the end of the study period. After adjustment for illness severity, patient deaths, and other factors, the average annual per patient expenditure declined from $20,300 to $18,300 during the same period.

Overall expenditures for HIV care declined in all patient groups, but not all HIV patients saw a shift from hospital to outpatient care. By late 1998, hospital care remained the largest treatment cost item for members of underserved groups, accounting for up to half of all spending for HIV care of women, blacks, and patients in the Eastern region of the United States, as well as HIV patients whose care was paid for by the Medicaid program. In contrast, 75 to 90 percent of the money spent for treating other HIV patients went toward outpatient drug therapy and clinic visits.

These findings indicate that highly active combination antiretroviral therapy reduced the need for expensive hospital inpatient care among HIV patients as a whole, but it did not affect disadvantaged patient groups to the same degree. Another concern is that demand for inpatient care may be on the rebound for all HIV patient groups, according to the HCSUS co-principal investigator and the study's lead author, Samuel A. Bozzette, M.D., Ph.D., a senior scientist with RAND and professor of medicine at the University of California, San Diego. Dr. Bozzette, who also heads the health services research unit of the Veterans Affairs Hospital in San Diego, notes that there have been recent reports of treatment failures involving highly active combination antiretroviral therapy and that expenditures for the hospital care of HIV patients appeared to be rising by the end of 1998.

For this project, which was also supported by the Health Resources and Services Administration and other components of the Department of Health and Human Services, the researchers periodically interviewed a randomly selected sample initially consisting of 2,864 adult HIV patients.

For more details, see "Expenditures for HIV care in the era of highly active therapy: Results from the HIV Cost and Services Utilization Study," by Dr. Bozzette, Geoffrey Joyce, Ph.D., Daniel F. McCaffrey, Ph.D., and others, in the March 15, 2001, New England Journal of Medicine 344, pp. 817-823.

Return to Contents
Proceed to Next Article

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care